Biobetters Market Report 2026

The biobetters market size has grown rapidly in recent years. It will grow from $75.29 billion in 2025 to $83.84 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to rising prevalence of chronic diseases, increased awareness about biosimilars, advancements in biotechnology, supportive government initiatives, growing geriatric population.

The biobetters market size is expected to see strong growth in the next few years. It will grow to $121.61 billion in 2030 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing adoption of biobetters over original biologics, technological innovations in drug delivery systems, expansion of healthcare infrastructure in emerging markets, partnerships and collaborations in biopharma, rising demand for personalized medicine. Major trends in the forecast period include enhanced drug efficacy and safety, optimized dosing regimens, improved stability and shelf life, convenient administration methods, expansion in chronic disease treatment.

The increasing prevalence of chronic kidney disease is anticipated to drive expansion in the biobetters market. Chronic kidney disease (CKD) is a persistent condition where the kidneys gradually lose their capacity to remove waste and maintain vital body functions. CKD rates are climbing due to older populations, higher diabetes and hypertension cases, inactive lifestyles, and advances in diagnostics. Biobetters aid CKD treatment through drugs that provide superior effectiveness, safer profiles, and optimized administration schedules relative to first-generation biologics. For example, in June 2023, Oxford Academic - a UK-based research platform - reported that CKD cases in the UK are expected to grow from 0.00827 billion in 2022 to 0.00861 billion by 2032, a 4% rise. Thus, the growing burden of chronic kidney disease is fueling biobetters market growth.

The growing incidence of autoimmune diseases is anticipated to boost the biobetters market in the future. Autoimmune diseases occur when the immune system erroneously targets the body's healthy cells and tissues. This surge stems from genetic predispositions, environmental factors, and contemporary lifestyle influences. Biobetters aid in managing autoimmune conditions through biologic therapies that deliver superior efficacy, fewer adverse effects, optimized dosing schedules, and better stability compared to their predecessor biologics. For example, in September 2023, the Impact of IBD Report 2023 from the IBD Clinical and Research Centre - a Canadian non-profit - reported that inflammatory bowel disease (IBD) prevalence in Canada hit 825 cases per 100,000 people in 2023, affecting over 0.00032 billion individuals, with forecasts showing a climb to 0.00047 billion Canadians by 2035 amid yearly increases. Thus, the rising prevalence of autoimmune diseases is fueling expansion in the biobetters market.

Major companies in the biobetters market are prioritizing the development of biobetters for subcutaneous delivery to boost patient convenience, improve treatment results, and lower healthcare costs overall. Subcutaneous administration of biobetters involves injecting biologic therapies under the skin instead of using traditional intravenous infusions, which cuts administration time, increases comfort, and supports better adherence for patients with chronic illnesses. For example, in May 2023, Celltrion, a biopharmaceutical firm based in South Korea, gained approval from the Brazilian Health Regulatory Agency for Remsima SC - a subcutaneous biobetter of its infliximab biosimilar Remsima - targeted at inflammatory bowel diseases like Crohn’s disease and ulcerative colitis. This product marks the world's first subcutaneous infliximab option, delivering greater accessibility, superior convenience over IV infusions, and prospects for stronger clinical results in ongoing disease control.

Major companies operating in the biobetters market are Amgen Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., Sanofi Aventis LLC, Pfizer Inc., Novartis AG, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., CSL Behring GmbH, Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson, Bayer AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Celltrion Inc., Teva Pharmaceutical Industries Ltd., Lonza Group AG, GRIFOLS USA LLC.

North America was the largest region in the biobetters market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biobetters market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biobetters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the biobetters market by raising the cost of imported raw materials, biologic reagents, and manufacturing equipment, leading to higher production expenses and potential delays. The most affected segments include monoclonal antibodies biobetters and insulin biobetters, particularly in regions like North America and Asia-Pacific, which are heavily reliant on global supply chains. While tariffs have posed challenges, they have also incentivized local production and innovation in drug formulation, potentially benefiting domestic manufacturers in the long term.

The biobetters market research report is one of a series of new reports that provides biobetters market statistics, including biobetters industry global market size, regional shares, competitors with a biobetters market share, detailed biobetters market segments, market trends and opportunities, and any further data you may need to thrive in the biobetters industry. This biobetters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biobetters are biologic drugs that resemble existing biologics yet feature enhancements for superior efficacy, safety, or additional clinical advantages. Such improvements might encompass optimized dosing schedules, fewer adverse effects, greater stability, or simpler delivery options, granting them an edge over the originator biologics.

The primary drug classes of biobetters include erythropoietin biobetters, granulocyte-colony stimulating factor (G-CSF) biobetters, interferon biobetters, insulin biobetters, monoclonal antibody biobetters, antihemophilic factors, and others. Erythropoietin biobetters represent enhanced versions of erythropoietin, a hormone that stimulates red blood cell production. They come in various routes of administration, such as oral, subcutaneous, inhaled, and intravenous, target different disease indications like diabetes, cancer, renal disease, neurodegenerative diseases, genetic disorders, and hemophilia, and are distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies.

The biobetters market consists of sales of next-generation biologics, improved formulation products, and biosimilar drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.